3,077 Shares in Inspire Medical Systems, Inc. (NYSE:INSP) Purchased by Aigen Investment Management LP

Aigen Investment Management LP acquired a new stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 3,077 shares of the company's stock, valued at approximately $649,000.

A number of other hedge funds have also recently bought and sold shares of the business. SouthState Corp bought a new stake in Inspire Medical Systems in the second quarter valued at $27,000. Farther Finance Advisors LLC lifted its position in Inspire Medical Systems by 1,158.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 151 shares of the company's stock valued at $32,000 after purchasing an additional 139 shares during the last quarter. GAMMA Investing LLC boosted its stake in Inspire Medical Systems by 559.3% during the 3rd quarter. GAMMA Investing LLC now owns 178 shares of the company's stock valued at $38,000 after purchasing an additional 151 shares during the period. Quarry LP grew its position in Inspire Medical Systems by 105.4% in the 2nd quarter. Quarry LP now owns 343 shares of the company's stock worth $46,000 after purchasing an additional 176 shares during the last quarter. Finally, Daiwa Securities Group Inc. bought a new stake in shares of Inspire Medical Systems during the second quarter valued at approximately $53,000. Institutional investors and hedge funds own 94.91% of the company's stock.

Inspire Medical Systems Price Performance

Inspire Medical Systems stock traded down $7.50 during mid-day trading on Thursday, hitting $174.68. The company's stock had a trading volume of 479,989 shares, compared to its average volume of 600,773. Inspire Medical Systems, Inc. has a 52-week low of $123.00 and a 52-week high of $257.40. The firm's 50 day moving average is $203.04 and its 200 day moving average is $178.61. The company has a market cap of $5.23 billion, a PE ratio of 170.17 and a beta of 1.36.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.54. The firm had revenue of $203.20 million for the quarter, compared to analyst estimates of $197.59 million. Inspire Medical Systems had a net margin of 4.37% and a return on equity of 5.30%. The company's revenue for the quarter was up 32.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.29) EPS. As a group, analysts forecast that Inspire Medical Systems, Inc. will post 1.33 EPS for the current year.

Insiders Place Their Bets

In other news, insider Randy Ban sold 4,861 shares of Inspire Medical Systems stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $188.55, for a total transaction of $916,541.55. Following the completion of the sale, the insider now directly owns 3,056 shares in the company, valued at $576,208.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Inspire Medical Systems news, insider Randy Ban sold 4,861 shares of the firm's stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $188.55, for a total transaction of $916,541.55. Following the transaction, the insider now directly owns 3,056 shares in the company, valued at $576,208.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Shawn Mccormick sold 800 shares of the business's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $220.00, for a total value of $176,000.00. Following the completion of the sale, the director now directly owns 23,140 shares of the company's stock, valued at $5,090,800. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,692 shares of company stock valued at $1,099,207 in the last three months. Insiders own 4.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on INSP shares. Wells Fargo & Company boosted their price target on Inspire Medical Systems from $187.00 to $198.00 and gave the stock an "equal weight" rating in a research report on Tuesday, November 5th. Royal Bank of Canada reissued an "outperform" rating and issued a $260.00 price objective on shares of Inspire Medical Systems in a research note on Tuesday, November 5th. Truist Financial reaffirmed a "buy" rating and set a $240.00 target price (up previously from $217.00) on shares of Inspire Medical Systems in a research note on Monday, September 30th. Leerink Partners boosted their price target on shares of Inspire Medical Systems from $167.00 to $197.00 and gave the stock a "market perform" rating in a research report on Tuesday, September 10th. Finally, Robert W. Baird raised their price objective on shares of Inspire Medical Systems from $240.00 to $252.00 and gave the company an "outperform" rating in a research report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Inspire Medical Systems presently has an average rating of "Moderate Buy" and a consensus target price of $227.75.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.